4Q23 results included charges related to the Daiichi Sankyo collaboration .

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

The S&P 500 added 0.7% on Tuesday, Feb. 4, as investors evaluated developments on U.S. tariffs, labor market data, and the latest earnings news.

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Merck (MRK) stock is sinking 10% after the company provided weaker-than-expected 2025 guidance amid weak sales of Gardasil, its HPV vaccine. Additionally, the huge drug maker withdrew its long-term ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...